MeiraGTx is evolving into a late-stage, manufacturing-enabled genetic medicine company with multiple near-term regulatory catalysts. MGTX's robust manufacturing infrastructure and targeted therapies, such as Bota-vec and AAV2-hAQP1, position it for commercial inflection without mass-market commercialization burdens. Recent equity raise and anticipated milestone payments extend MGTX's cash runway through 2H 2028, supporting execution of late-stage programs.
